According to Dian Diagnosis, on August 30, during the 37th National Academic Conference of the China Tuberculosis Association, Dian Diagnosis held a “press conference on the achievements of the first domestic dual-sample tuberculosis molecular testing technology”. The Jindian® Mycobacterium tuberculosis complex nucleic acid detection kit released this time was developed by Dian Biotech, a subsidiary of Dean Diagnostics, in cooperation with the Shanghai Infectious Disease and Immunology Science and Technology Innovation Center, and has obtained a registration certificate for three types of medical devices from the State Drug Administration. The product supports two sample types: non-invasive tongue swab sampling and traditional sputum sampling. One set of reagents can balance scenarios such as clinical diagnosis and treatment and large-scale active public health screening, and achieve a seamless connection between traditional testing routes and innovative non-invasive testing.

According to Dian Diagnosis, on August 30, during the 37th National Academic Conference of the China Tuberculosis Association, Dian Diagnosis held a “press conference on the achievements of the first domestic dual-sample tuberculosis molecular testing technology”. The Jindian® Mycobacterium tuberculosis complex nucleic acid detection kit released this time was developed by Dian Biotech, a subsidiary of Dean Diagnostics, in cooperation with the Shanghai Infectious Disease and Immunology Science and Technology Innovation Center, and has obtained a registration certificate for three types of medical devices from the State Drug Administration. The product supports two sample types: non-invasive tongue swab sampling and traditional sputum sampling. One set of reagents can balance scenarios such as clinical diagnosis and treatment and large-scale active public health screening, and achieve a seamless connection between traditional testing routes and innovative non-invasive testing.